03:07 I would like to quickly
03:10 discuss what I believe is in the minds
03:13 of most of our shareholders which is
03:16 canceiied align fund itself to get to
03:20 revenue the simple and short answer is
03:25 we believe we can do this and we believe
03:29 we can do this much easier than the last
03:33 four years
09:00 we are evaluating offers for the right
09:04 of commercialization of leronlimab for
09:07 certain indication for several millions
09:10 of dollars of upfront payment and
09:13 milestone payments we are in the process
09:16 of evaluating our counteroffer to these
09:19 offers detail of whether we accept or
09:22 reject any of these offers will be
09:24 shared with everyone at an appropriate
09:27 time
10:24 I'm very
10:29 pleased so now that sided ein currently
10:32 is in discussions with a major biologic
10:35 CMO a large biological manufacturing
10:38 company this company has given us an
10:40 offer
10:42 to produce over 500 million dollars
10:45 worth of commercial product this amount
10:48 is again based on 120,000 per year per
10:50 session and the half a billion
27:22 as I just
27:24 mentioned we now have offers on the
27:26 table for significant amount of upfront
27:29 non diluted cash and milestones now we
27:33 will send our counteroffer and the
27:36 shareholders will know exact situation
27:39 with these offers at the appropriate
27:41 time
32:09 commercialize itself well as I said
32:12 right now there is many offers on the
32:14 table that we were working I believe
32:16 zoom up the last product that was
32:18 humanized monoclonal antibody got
32:19 commercialized they made a deal with
32:21 another company
33:23 of the finances well we just explained
33:25 half a billion dollar water product is
33:29 offered to us to be made by a very
33:32 credible CMO and we are very excited
33:37 because the payments for it is deferred
33:39 to the end of 2020
34:06 to ask a question that you know that I
34:07 had asked there and can you further
34:10 clarify or describe some of the out
34:12 licensing activities that you might do
34:14 and specifically whether these
34:15 partnerships that you're looking for are
34:17 in specific fields of use and whether
34:21 the partners are already in these fields
34:24 of use so a transition you know with
34:26 Lorana lab might be easier or is this
34:29 opt or is this going to be a field of
34:31 use that is also new to the partner
34:33 company that's a very good question I
34:36 appreciate that shine it was great
34:38 meeting you at the conference we are
34:41 working with few different
34:43 commercialization company few of them
34:45 have told us that they are already in
34:47 HIV and they are
34:49 very happy to go to HIV the ones that
34:52 haven't been in HIV so that was no
34:54 problem but very soon
35:34 and we are very happy that we see they
35:37 are there are offers there are people
35:40 who really say hey we all definitely
35:42 understand this there are very large
35:45 pharmaceuticals that are coming to the
35:48 table and there are very large
35:49 manufacturing which companies are saying
35:52 that they're willing to risk and make
35:54 all the product for us even though we
35:56 don't have approval yet but they're
35:57 willing to start that process for half a
35:59 billion dollar worth of products so it's
36:02 a major thing
43:03 they're telling us it's time to stop
43:05 raising funds and try to materialize one
43:09 of these deals they're helping us with
43:11 these deals event so we can't go forward
43:14 without raising funds because they want
43:16 the shareholders that came through them
43:18 to have maximum benefit and we're
43:21 working together and we look forward to
43:23 put out some news that would give you
43:25 more clarity about what
6:13 stop making sure that everything is in
46:15 place for us to have success and the way
46:17 we're going we hit our primary end point
46:19 we don't think something that everybody
46:22 could take some comfort but the stock
46:25 price is in our mind that's why Paul
46:27 Sartre has also accepted to help us with
46:30 the event that we are putting on
46:32 February 28th not that we are going to
46:34 raise money from the because for this
46:37 event that's absolutely not the case
46:39 we're not even allowed to have anybody
46:41 in that place to participate in any
46:43 fundraising because of SEC rules and
46:46 regulations which we follow very closely
46:48 so we are wanting to have enough
46:53 visibility so people can see what we
46:56 have and those people who check out our
46:58 science and just dig in a little bit to
47:00 go while we impress
50:32 we believe we have a number of clinical
50:40 developments between now and the balance
50:44 of the year that that is going to that
50:47 has a strong potential of possibly
50:51 having a very positive effect on the
50:54 valuation of the company and that's why
50:57 we are looking at we are raising capital
51:00 at a very judicious pace to ensure that
51:05 we're being as opportunistic as possible
51:07 on what we believe our future valuation
51:12 catalysts for the shareholders
03:10 discuss what I believe is in the minds
03:13 of most of our shareholders which is
03:16 canceiied align fund itself to get to
03:20 revenue the simple and short answer is
03:25 we believe we can do this and we believe
03:29 we can do this much easier than the last
03:33 four years
09:00 we are evaluating offers for the right
09:04 of commercialization of leronlimab for
09:07 certain indication for several millions
09:10 of dollars of upfront payment and
09:13 milestone payments we are in the process
09:16 of evaluating our counteroffer to these
09:19 offers detail of whether we accept or
09:22 reject any of these offers will be
09:24 shared with everyone at an appropriate
09:27 time
10:24 I'm very
10:29 pleased so now that sided ein currently
10:32 is in discussions with a major biologic
10:35 CMO a large biological manufacturing
10:38 company this company has given us an
10:40 offer
10:42 to produce over 500 million dollars
10:45 worth of commercial product this amount
10:48 is again based on 120,000 per year per
10:50 session and the half a billion
27:22 as I just
27:24 mentioned we now have offers on the
27:26 table for significant amount of upfront
27:29 non diluted cash and milestones now we
27:33 will send our counteroffer and the
27:36 shareholders will know exact situation
27:39 with these offers at the appropriate
27:41 time
32:09 commercialize itself well as I said
32:12 right now there is many offers on the
32:14 table that we were working I believe
32:16 zoom up the last product that was
32:18 humanized monoclonal antibody got
32:19 commercialized they made a deal with
32:21 another company
33:23 of the finances well we just explained
33:25 half a billion dollar water product is
33:29 offered to us to be made by a very
33:32 credible CMO and we are very excited
33:37 because the payments for it is deferred
33:39 to the end of 2020
34:06 to ask a question that you know that I
34:07 had asked there and can you further
34:10 clarify or describe some of the out
34:12 licensing activities that you might do
34:14 and specifically whether these
34:15 partnerships that you're looking for are
34:17 in specific fields of use and whether
34:21 the partners are already in these fields
34:24 of use so a transition you know with
34:26 Lorana lab might be easier or is this
34:29 opt or is this going to be a field of
34:31 use that is also new to the partner
34:33 company that's a very good question I
34:36 appreciate that shine it was great
34:38 meeting you at the conference we are
34:41 working with few different
34:43 commercialization company few of them
34:45 have told us that they are already in
34:47 HIV and they are
34:49 very happy to go to HIV the ones that
34:52 haven't been in HIV so that was no
34:54 problem but very soon
35:34 and we are very happy that we see they
35:37 are there are offers there are people
35:40 who really say hey we all definitely
35:42 understand this there are very large
35:45 pharmaceuticals that are coming to the
35:48 table and there are very large
35:49 manufacturing which companies are saying
35:52 that they're willing to risk and make
35:54 all the product for us even though we
35:56 don't have approval yet but they're
35:57 willing to start that process for half a
35:59 billion dollar worth of products so it's
36:02 a major thing
43:03 they're telling us it's time to stop
43:05 raising funds and try to materialize one
43:09 of these deals they're helping us with
43:11 these deals event so we can't go forward
43:14 without raising funds because they want
43:16 the shareholders that came through them
43:18 to have maximum benefit and we're
43:21 working together and we look forward to
43:23 put out some news that would give you
43:25 more clarity about what
6:13 stop making sure that everything is in
46:15 place for us to have success and the way
46:17 we're going we hit our primary end point
46:19 we don't think something that everybody
46:22 could take some comfort but the stock
46:25 price is in our mind that's why Paul
46:27 Sartre has also accepted to help us with
46:30 the event that we are putting on
46:32 February 28th not that we are going to
46:34 raise money from the because for this
46:37 event that's absolutely not the case
46:39 we're not even allowed to have anybody
46:41 in that place to participate in any
46:43 fundraising because of SEC rules and
46:46 regulations which we follow very closely
46:48 so we are wanting to have enough
46:53 visibility so people can see what we
46:56 have and those people who check out our
46:58 science and just dig in a little bit to
47:00 go while we impress
50:32 we believe we have a number of clinical
50:40 developments between now and the balance
50:44 of the year that that is going to that
50:47 has a strong potential of possibly
50:51 having a very positive effect on the
50:54 valuation of the company and that's why
50:57 we are looking at we are raising capital
51:00 at a very judicious pace to ensure that
51:05 we're being as opportunistic as possible
51:07 on what we believe our future valuation
51:12 catalysts for the shareholders
